- Home
- AHG vs ORIC Comparison
AHG vs ORIC Comparison
Compare AHG & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | ORIC |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.5M | 783.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AHG | ORIC |
|---|---|---|
| Price | $1.60 | $8.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 20.1K | ★ 1.4M |
| Earning Date | 12-15-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,777,798.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 512.09 | N/A |
| 52 Week Low | $0.83 | $3.90 |
| 52 Week High | $2.10 | $14.93 |
Technical Indicators
Market Signals| Indicator | AHG | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 28.24 |
| Support Level | $1.27 | $7.96 |
| Resistance Level | $1.70 | $8.44 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 79.59 | 10.92 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.